SCHEMBL17299693

SCHEMBL17299693

CC(C)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 7/20 0.65
▸ CNR1 P21554 4/20 0.65
▸ PPARG P37231 3/20 0.65
▸ CYP1A2 P05177 3/20 0.65
▸ CYP3A4 P08684 3/20 0.65
▸ HPGD P15428 2/20 0.65
▸ MEN1 O00255 2/20 0.65
▸ MAPT P10636 2/20 0.65
▸ CYP2C19 P33261 2/20 0.65
▸ KMT2A Q03164 2/20 0.65
▸ ABCB11 O95342 2/20 0.65
▸ TSHR P16473 2/20 0.65
▸ HTR2A P28223 2/20 0.65
▸ PMP22 Q01453 2/20 0.65
▸ MAPK1 P28482 2/20 0.65
▸ LMNA P02545 2/20 0.65
▸ USP2 O75604 1/20 0.65
▸ ADORA3 P0DMS8 1/20 0.65
▸ CYP2C9 P11712 1/20 0.65
▸ ADRB3 P13945 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2742865 0.87 PPARA (0.65) PPARACNR1PPARGCYP1A2CYP3A4
SCHEMBL17299692 0.86 PPARA (0.50) PPARACNR1PPARGCYP1A2CYP3A4
SCHEMBL10971208 0.86 PPARA (0.63) PPARACNR1PPARGCYP1A2CYP3A4
SCHEMBL19597518 0.84 PPARA (0.61) PPARACNR1PPARGCYP1A2CYP3A4
SCHEMBL10190646 0.83 PPARA (0.73) PPARACNR1PPARGCYP1A2CYP3A4
SCHEMBL30657556 0.80 PPARA (0.69) PPARACNR1PPARGCYP1A2CYP3A4
Fenofibrate SCHEMBL3876232 0.79 PPARA (1.00) PPARACNR1PPARGCYP1A2CYP3A4
Fenofibrate SCHEMBL4670 0.79 PPARA (1.00) PPARACNR1PPARGCYP1A2CYP3A4
SCHEMBL822492 0.79 PPARA (0.77) PPARACNR1PPARGCYP1A2CYP3A4
SCHEMBL13984052 0.79 PPARA (0.77) PPARACNR1PPARGCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2017-05-25 — — US disclosed
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2017-05-25 — — US disclosed
US-20150344430-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2015-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344430-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 PPARA 196/4885CNR1 2881/4885PPARG 285/4885
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 PPARA 196/4885CNR1 2881/4885PPARG 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback